Cleveland Biolabs Inc (NASDAQ:CBLI) Institutional Investor Positioning Change

February 2, 2018 - By Marie Mckinney

 Cleveland Biolabs Inc (NASDAQ:CBLI) Institutional Investor Positioning Change

Sentiment for Cleveland Biolabs Inc (NASDAQ:CBLI)

Cleveland Biolabs Inc (NASDAQ:CBLI) institutional sentiment decreased to 1.5 in Q3 2017. Its down -8.50, from 10 in 2017Q2. The ratio fall, as 6 funds started new or increased holdings, while 4 sold and reduced their stakes in Cleveland Biolabs Inc. The funds in our partner’s database reported: 438,124 shares, down from 1.03 million shares in 2017Q2. Also, the number of funds holding Cleveland Biolabs Inc in their top 10 holdings was flat from 0 to 0 for the same number . Sold All: 2 Reduced: 2 Increased: 3 New Position: 3.

Cleveland BioLabs, Inc., a biopharmaceutical company, develops novel approaches to activate the immune system and address various medical needs in the United States and the Russian Federation. The company has market cap of $39.14 million. The companyÂ’s advanced product candidate is entolimod, a Toll-like receptor 5 agonist that is used to prevent death from acute radiation syndrome, and as an oncology drug. It currently has negative earnings. It is also developing CBLB612, a pharmacologically optimized synthetic molecule that structurally mimics naturally occurring lipopeptides of Mycoplasma, and activates NF-kB pro-survival and immunoregulatory signaling pathways; and Mobilan, a recombinant non-replicating adenovirus that directs expression of TLR5 and its agonistic ligand.

The stock decreased 2.80% or $0.1 during the last trading session, reaching $3.47. About 16,395 shares traded. Cleveland BioLabs, Inc. (NASDAQ:CBLI) has risen 63.33% since February 2, 2017 and is uptrending. It has outperformed by 46.63% the S&P500.

Thompson Davis & Co. Inc. holds 0.01% of its portfolio in Cleveland BioLabs, Inc. for 1,334 shares. Bank Of America Corp De owns 100 shares or 0% of their US portfolio. Moreover, Bank Of Montreal Can has 0% invested in the company for 31 shares. The New York-based Blackrock Inc. has invested 0% in the stock. Citadel Advisors Llc, a Illinois-based fund reported 10,032 shares.#img1#

More notable recent Cleveland BioLabs, Inc. (NASDAQ:CBLI) news were published by: Thestreet.com which released: “Cleveland BioLabs (CBLI) Stock Spikes on $25 Million Equity Financing Agreement” on June 25, 2015, also Reuters.com with their article: “North Korea threats spur US search for new radiation therapies” published on January 31, 2018, Seekingalpha.com published: “Cleveland BioLabs’ Anti-Radiation Drug Makes It A Tempting Speculative Buy” on September 17, 2012. More interesting news about Cleveland BioLabs, Inc. (NASDAQ:CBLI) were released by: Marketwired.com and their article: “Cleveland BioLabs Announces Commencement of In Vivo Biocomparability Study” published on April 17, 2017 as well as Marketwired.com‘s news article titled: “Cleveland BioLabs Announces the Successful Completion of a Phase 1 Study of …” with publication date: April 16, 2014.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.